从HER-2检测研究进展谈转化医学在乳腺癌诊治中的重要作用
HER-2是乳腺癌诊疗过程中重要的预后指标和靶向HER-2药物的预测指标，准确判断HER-2状态对于乳腺癌病人治疗方案的制定具有重要的指导作用。临床常规的HER-2检测手段包括免疫组化（IHC）和荧光原位杂交（FISH）两种方法。
摘要：
HER-2是乳腺癌诊疗过程中重要的预后指标和靶向HER-2药物的预测指标，准确判断HER-2状态对于乳腺癌病人治疗方案的制定具有重要的指导作用。临床常规的HER-2检测手段包括免疫组化（IHC）和荧光原位杂交（FISH）两种方法。但是，随着乳腺癌临床治疗理念的不断发展，上述两种方法在检测的时效性、动态性、准确性等方面均无法满足临床的需求。外周血HER-2 ECD及循环肿瘤细胞（CTC）的HER-2检测有望弥补IHC和FISH的不足。
关键词： 乳腺癌 转化医学 HER-2
Abstract:
The advances in human epidermal growth factor receptor 2(HER-2) testing: the important role of translational medicine in treatment of breast cancer LIU Yi, LIU Bing, JIANG Ze-Fei. Affiliated Hospital of Academy of Military Medical Sciences（307 Hospital），Beijing 100071, China
Corresponding author： JIANG Ze-fei,E-mail：jiangzefei@medmail.com.cn
Abstract Human epidermal growth factor receptor 2 (HER-2) status is considered to be a vital prognostic and predictive factor for therapeutic decision making in breast cancer.The conventional methods that used in clinical practice now are immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Nevertheless, with the development of treatment concept in breast cancer, both IHC and FISH could not satisfy the clinical demand in real-time, dynamic and accuracy. HER-2 detection with HER-2 extra cellular domain (ECD) and circulating tumor cells (CTC) in blood were expected to settle the problems.
Keywords: breast cancer translational medicine human epidermal growth factor receptor 2 (HER-2)
相关文章
评论
我要跟帖
